In this interview with Clinical Trial Vanguard, Cereno Scientific CEO Sten Sorensen and CMO Rahul Argawal explain that epigenetic modulation of key pathophysiological pathways can do what vasodilation cannot: slow, halt, and potentially reverse the vascular remodelling that drives the relentless progression of pulmonary arterial hypertension (PAH).

Cereno's leaders also talked about the science behind Cereno's approach, the upcoming Phase IIb trial of lead asset CS1, and how this could impact on the lives of those living with PAH on a daily basis. 

Read the full article here.